Michael J. De Veer

Dr. Michael J. De Veer


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2017 in Respiratory Research
Verified
Journal Article
Open access
PDF file
MKMagdalena Kołodziej
Magdalena Kołodziej
MVMichael J. De Veer
Michael J. De Veer
MCMarian Cholewa
Marian Cholewa
GEGary F Egan
Gary F Egan
BTBruce R. Thompson
Bruce R. Thompson
Monitoring of pulmonary physiology is fundamental to the clinical management of patients with Cystic Fibrosis. The current standard clinical practise uses spirometry to assess lung function which delivers a clinically relevant functional readout of total lung function, however does not supply any visible or localised information. High Resolution Computed Tomography (HRCT) is a well-established current ‘gold standard’ method for monitoring lung anatomical changes in Cystic Fibrosis patients. HRCT provides excellent morphological information, however, the X-ray radiation dose can become significant if multiple scans are required to monitor chronic diseases such as cystic fibrosis. X-ray phase-contrast imaging is another emerging X-ray based methodology for Cystic Fibrosis lung assessment which provides dynamic morphological and functional information, albeit with even higher X-ray doses than HRCT. Magnetic Resonance Imaging (MRI) is a non-ionising radiation imaging method that is garnering growing interest among researchers and clinicians working with Cystic Fibrosis patients. Recent advances in MRI have opened up the possibilities to observe lung function in real time to potentially allow sensitive and accurate assessment of disease progression. The use of hyperpolarized gas or non-contrast enhanced MRI can be tailored to clinical needs. While MRI offers significant promise it still suffers from poor spatial resolution and the development of an objective scoring system especially for ventilation assessment.

1 October 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MNMelanie Neeland
Melanie Neeland
WSWei Shi
Wei Shi
CCCatherine Collignon
Catherine Collignon
NTNadine Taubenheim
Nadine Taubenheim
EMEls Meeusen
Els Meeusen
MVMichael J. De Veer
Michael J. De Veer
The liposome-based adjuvant AS01 incorporates two immune stimulants, 3-O-desacyl-4′-monophosphoryl lipid A and the saponin QS-21. AS01 is under investigation for use in several vaccines in clinical development. i.m. injection of AS01 enhances immune cell activation and dendritic cell (DC) Ag presentation in the local muscle-draining lymph node. However, cellular and Ag trafficking in the lymphatic vessels that connect an i.m. injection site with the local lymph node has not been investigated. The objectives of this study were: 1) to quantify the in vivo cellular immune response induced by AS01 in an outbred ovine model, 2) to develop a lymphatic cannulation model that directly collects lymphatic fluid draining the muscle, and 3) to investigate the function of immune cells entering and exiting the lymphatic compartments after s.c. or i.m. vaccination with AS01 administered with hepatitis B surface Ag (HBsAg). We show that HBsAg-AS01 induces a distinct immunogenic cellular signature within the blood and draining lymphatics following both immunization routes. We reveal that MHCIIhigh migratory DCs, neutrophils, and monocytes can acquire Ag within muscle and s.c. afferent lymph, and that HBsAg-AS01 uniquely induces the selective migration of Ag-positive neutrophils, monocytes, and an MHCIIhigh DC-like cell type out of the lymph node via the efferent lymphatics that may enhance Ag-specific immunity. We report the characterization of the immune response in the lymphatic network after i.m. and s.c. injection of a clinically relevant vaccine, all in real time using a dose and volume comparable with that administered in humans.

1 February 2013 in Vaccine
Verified
Journal Article
Closed access
MVMichael J. De Veer
Michael J. De Veer
MNMelanie Neeland
Melanie Neeland
MBMelissa Burke
Melissa Burke
JPJill Pleasance
Jill Pleasance
JNJackie Nathanielsz
Jackie Nathanielsz
EMEls Meeusen
Els Meeusen

7 June 2011 in Immunology & Cell Biology
Verified
Journal Article
Closed access
MVMichael J. De Veer
Michael J. De Veer
JKJoanna Kemp
Joanna Kemp
JCJosh Chatelier
Josh Chatelier
MEMartin J Elhay
Martin J Elhay
EMEls Meeusen
Els Meeusen

17 September 2013 in Innate Immunity
Verified
Journal Article
Closed access
MBMelissa L Burke
Melissa L Burke
MVMichael J. De Veer
Michael J. De Veer
JPJill Pleasance
Jill Pleasance
MNMelanie Neeland
Melanie Neeland
MEMartin Elhay
Martin Elhay
EMEls Meeusen
Els Meeusen
Many modern vaccines use defined adjuvants to stimulate the innate immune system and shape the adaptive immune response. The exact nature of these innate signals and whether immune differentiation can originate within the periphery is not known. Here we used an ovine lymphatic cannulation model to characterise the cellular and transcriptomic profile of the afferent lymph following injection of a liposomal vaccine formulation incorporating diphtheria toxoid and the innate stimulator poly(I:C) over a 78-h period. The response to this vaccine featured an early activation of broad pro-inflammatory pathways (e.g. TLR signalling and inflammasome pathways) and the transient recruitment of granulocytes into the lymph. At 24 h a more monocytic cellular profile arose coinciding with a transition to a specific antiviral response characterised by the up-regulation of genes associated with the receptors typical for the viral mimic, poly(I:C) (e.g. TLR3, RIG-I and MDA5). At the latest time points the up-regulation of IL-17A and IL-17F suggested that Th17 cells may participate in the earliest adaptive response to this vaccine. These data provide the most comprehensive picture of the cellular and molecular mechanisms that link the periphery to the draining lymph node following vaccination, and indicate that the immune response is capable of specialising within the periphery.

8 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ISIoanna Savvidou
Ioanna Savvidou
TKTiffany Khong
Tiffany Khong
SWSophie Whish
Sophie Whish
ICIrena (Iśka) Carmichael
Irena (Iśka) Carmichael
TSTara Sepehrizadeh
Tara Sepehrizadeh
Andrew SpencerAndrew Spencer
Andrew Spencer
Over the last three decades changes in the treatment paradigm for newly diagnosed multiple myeloma (MM) have led to a significant increase in overall survival. Despite this, the majority of patients relapse after one or more lines of treatment while acquiring resistance to available therapies. Panobinostat, a pan-histone deacetylase inhibitor, was approved by the FDA in 2015 for patients with relapsed MM but how to incorporate panobinostat most effectively into everyday practice remains unclear. Dysregulation of the Wnt canonical pathway, and its key mediator β-catenin, has been shown to be important for the evolution of MM and the acquisition of drug resistance, making it a potentially attractive therapeutic target. Despite concerns regarding the safety of Wnt pathway inhibitors, we have recently shown that the β-catenin inhibitor Tegavivint is deliverable and effective in in vivo models of MM. In this study we show that the combination of low concentrations of panobinostat and Tegavivint have significant in vitro and in vivo anti-MM effects including in the context of proteasome inhibitor resistance, by targeting both aerobic glycolysis and mitochondrial respiration and the down-regulation of down-stream β-catenin targets including myc, cyclinD1, and cyclinD2. The significant anti-MM effect of this novel combination warrants further evaluation for the treatment of MM patients with relapsed and/or refractory MM.